Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GDC-0941 plus carboplatin/paclitaxel with or without bevacizumab in untreated advanced or recurrent NSCLC
NL-OMON39705Phase 2Active, not recruiting
- Sponsor
- Genentech
- Start
- Jun 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of pictilisib in non-small cell lung cancer (NSCLC) (6 arms), sponsored by Genentech. Primary endpoint: Progression-free survival. Started Jun 2013; status: active, not recruiting.
02
Drugs
pictilisib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON39705.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39705.